Novel markers and therapies for patients with acute heart failure and renal dysfunction

Peter A. McCullough, John Jefferies

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background Acute kidney injury complicates decompensated heart failure in ∼33% of cases and is associated with morbidity and mortality; thus, we sought to systematically review this topic in order to summarize novel diagnostic and therapeutic approaches. Methods Structured PubMed searches on these topics were conducted in February 2014 and relevant literature was identified. The PubMed search identified a total of 192 articles that were individually screened for inclusion in this analysis, and 58 were included. Results Acute kidney injury, defined by substantial increases in serum creatinine, is associated consistently with prolonged length of stay, rehospitalization, and mortality. Biomarker studies suggested that natriuretic peptides are prognostic for shorter- and longer-term mortality. Novel proteins indicating kidney damage and albumin in the urine are associated with acute kidney injury. The most promising acute pharmacologic treatment appears to be serelaxin, which has been shown to improve acute heart failure symptoms, hemodynamic parameters, and renal function. Conclusions The presence of acute kidney injury results in worse clinical outcomes for patients with acute heart failure. Novel biomarkers and therapies hold the promise of improving both cardiac and renal outcomes in these patients.

Original languageEnglish (US)
Pages (from-to)312.e1-312.e22
JournalAmerican Journal of Medicine
Volume128
Issue number3
DOIs
StatePublished - Mar 1 2015
Externally publishedYes

Fingerprint

Acute Kidney Injury
Heart Failure
Kidney
PubMed
Mortality
Biomarkers
Natriuretic Peptides
Therapeutics
Albumins
Length of Stay
Creatinine
Hemodynamics
Urine
Morbidity
Serum
Proteins

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Novel markers and therapies for patients with acute heart failure and renal dysfunction. / McCullough, Peter A.; Jefferies, John.

In: American Journal of Medicine, Vol. 128, No. 3, 01.03.2015, p. 312.e1-312.e22.

Research output: Contribution to journalArticle

@article{61474e7912544fc3975ed20c1aba32b2,
title = "Novel markers and therapies for patients with acute heart failure and renal dysfunction",
abstract = "Background Acute kidney injury complicates decompensated heart failure in ∼33{\%} of cases and is associated with morbidity and mortality; thus, we sought to systematically review this topic in order to summarize novel diagnostic and therapeutic approaches. Methods Structured PubMed searches on these topics were conducted in February 2014 and relevant literature was identified. The PubMed search identified a total of 192 articles that were individually screened for inclusion in this analysis, and 58 were included. Results Acute kidney injury, defined by substantial increases in serum creatinine, is associated consistently with prolonged length of stay, rehospitalization, and mortality. Biomarker studies suggested that natriuretic peptides are prognostic for shorter- and longer-term mortality. Novel proteins indicating kidney damage and albumin in the urine are associated with acute kidney injury. The most promising acute pharmacologic treatment appears to be serelaxin, which has been shown to improve acute heart failure symptoms, hemodynamic parameters, and renal function. Conclusions The presence of acute kidney injury results in worse clinical outcomes for patients with acute heart failure. Novel biomarkers and therapies hold the promise of improving both cardiac and renal outcomes in these patients.",
author = "McCullough, {Peter A.} and John Jefferies",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.amjmed.2014.10.035",
language = "English (US)",
volume = "128",
pages = "312.e1--312.e22",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Novel markers and therapies for patients with acute heart failure and renal dysfunction

AU - McCullough, Peter A.

AU - Jefferies, John

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background Acute kidney injury complicates decompensated heart failure in ∼33% of cases and is associated with morbidity and mortality; thus, we sought to systematically review this topic in order to summarize novel diagnostic and therapeutic approaches. Methods Structured PubMed searches on these topics were conducted in February 2014 and relevant literature was identified. The PubMed search identified a total of 192 articles that were individually screened for inclusion in this analysis, and 58 were included. Results Acute kidney injury, defined by substantial increases in serum creatinine, is associated consistently with prolonged length of stay, rehospitalization, and mortality. Biomarker studies suggested that natriuretic peptides are prognostic for shorter- and longer-term mortality. Novel proteins indicating kidney damage and albumin in the urine are associated with acute kidney injury. The most promising acute pharmacologic treatment appears to be serelaxin, which has been shown to improve acute heart failure symptoms, hemodynamic parameters, and renal function. Conclusions The presence of acute kidney injury results in worse clinical outcomes for patients with acute heart failure. Novel biomarkers and therapies hold the promise of improving both cardiac and renal outcomes in these patients.

AB - Background Acute kidney injury complicates decompensated heart failure in ∼33% of cases and is associated with morbidity and mortality; thus, we sought to systematically review this topic in order to summarize novel diagnostic and therapeutic approaches. Methods Structured PubMed searches on these topics were conducted in February 2014 and relevant literature was identified. The PubMed search identified a total of 192 articles that were individually screened for inclusion in this analysis, and 58 were included. Results Acute kidney injury, defined by substantial increases in serum creatinine, is associated consistently with prolonged length of stay, rehospitalization, and mortality. Biomarker studies suggested that natriuretic peptides are prognostic for shorter- and longer-term mortality. Novel proteins indicating kidney damage and albumin in the urine are associated with acute kidney injury. The most promising acute pharmacologic treatment appears to be serelaxin, which has been shown to improve acute heart failure symptoms, hemodynamic parameters, and renal function. Conclusions The presence of acute kidney injury results in worse clinical outcomes for patients with acute heart failure. Novel biomarkers and therapies hold the promise of improving both cardiac and renal outcomes in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84924047638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924047638&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2014.10.035

DO - 10.1016/j.amjmed.2014.10.035

M3 - Article

VL - 128

SP - 312.e1-312.e22

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 3

ER -